Biosimilar Newsletter Archive

31. 11.14.24 -- What's Next After FDA's DSCSA Extension? 11/14/2024
    11/14/24 Biosimilar Development Newsletter
32. 11.07.24 -- Reduce Time To Market With Efficient Vial Selection 11/7/2024

    11/07/24 Biosimilar Development Newsletter

33. 11.07.24 -- Data Quality Issues At The Heart Of FDA's DSCSA Troubles 11/7/2024
    11/07/24 Biosimilar Development Newsletter
34. 10.31.24 -- Key Considerations For Aseptic Filling 10/31/2024

    10/31/24 Biosimilar Development Newsletter

35. 10.31.24 -- Is The Downstream Biomanufacturing Bottleneck Over? 10/31/2024
    10/31/24 Biosimilar Development Newsletter
36. 10.24.24 -- Why Aren't QC Labs Fully Automated Yet? 10/24/2024
    10/24/24 Biosimilar Development Newsletter
37. 10.18.24 -- Resources For Trouble-Free Validation 10/18/2024

    10/18/24 Biosimilar Development Newsletter

38. 10.17.24 -- Outsourcing Considerations For Complex Protein Development 10/17/2024
    10/17/24 Biosimilar Development Newsletter
39. 10.16.24 -- Curious About Diverse Antibodies? 10/16/2024

    10/16/24 Biosimilar Development Newsletter

40. 10.10.24 -- Tips For Addressing Vaccine Demand – No Matter Your Therapeutic Background 10/10/2024

    10/10/24 Biosimilar Development Newsletter